62 related articles for article (PubMed ID: 24192755)
1. Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.
Hernández-Parra H; Cortés H; Avalos-Fuentes JA; Del Prado-Audelo M; Florán B; Leyva-Gómez G; Sharifi-Rad J; Cho WC
J Nanobiotechnology; 2022 Sep; 20(1):413. PubMed ID: 36109747
[TBL] [Abstract][Full Text] [Related]
2. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease.
Chen Y; Cai X; Xu R
AMIA Annu Symp Proc; 2015; 2015():1851-60. PubMed ID: 26958284
[TBL] [Abstract][Full Text] [Related]
3. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.
Stern AM; Schurdak ME; Bahar I; Berg JM; Taylor DL
J Biomol Screen; 2016 Jul; 21(6):521-34. PubMed ID: 26962875
[TBL] [Abstract][Full Text] [Related]
4. A quantitative system pharmacology computer model for cognitive deficits in schizophrenia.
Geerts H; Roberts P; Spiros A
CPT Pharmacometrics Syst Pharmacol; 2013 Apr; 2(4):e36. PubMed ID: 23887686
[TBL] [Abstract][Full Text] [Related]
5. Hallmarks of neurodegenerative disease: A systems pharmacology perspective.
Bloomingdale P; Karelina T; Ramakrishnan V; Bakshi S; Véronneau-Veilleux F; Moye M; Sekiguchi K; Meno-Tetang G; Mohan A; Maithreye R; Thomas VA; Gibbons F; Cabal A; Bouteiller JM; Geerts H
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1399-1429. PubMed ID: 35894182
[TBL] [Abstract][Full Text] [Related]
6. Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer's Disease.
Geerts H; van der Graaf P
J Alzheimers Dis Rep; 2021; 5(1):815-826. PubMed ID: 34966890
[TBL] [Abstract][Full Text] [Related]
7. Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare.
Kadra G; Spiros A; Shetty H; Iqbal E; Hayes RD; Stewart R; Geerts H
J Psychopharmacol; 2018 Nov; 32(11):1191-1196. PubMed ID: 30232932
[TBL] [Abstract][Full Text] [Related]
8. A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.
Roberts P; Spiros A; Geerts H
Front Pharmacol; 2016; 7():6. PubMed ID: 26869923
[TBL] [Abstract][Full Text] [Related]
9. Budipine in Parkinson's tremor.
Reichmann H
J Neurol Sci; 2006 Oct; 248(1-2):53-5. PubMed ID: 16784759
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform.
Spiros A; Roberts P; Geerts H
J Parkinsons Dis; 2013; 3(4):569-80. PubMed ID: 24192755
[TBL] [Abstract][Full Text] [Related]
11. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
12. Rasagiline treatment effects on parkinsonian tremor.
Lew MF
Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
[TBL] [Abstract][Full Text] [Related]
13. A bidirectional drug repositioning approach for Parkinson's disease through network-based inference.
Rakshit H; Chatterjee P; Roy D
Biochem Biophys Res Commun; 2015 Feb; 457(3):280-7. PubMed ID: 25576361
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological treatment of parkinsonian tremor].
Yokochi F
Nihon Rinsho; 2000 Oct; 58(10):2091-5. PubMed ID: 11068452
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
